Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211763 | 1.00 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL302512 | 1.00 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL302663 | 1.00 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL27828947 | 1.00 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL2182381 | 0.98 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL586117 | 0.92 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL8549614 | 0.90 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL8373505 | 0.90 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL8373486 | 0.90 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL3113016 | 0.90 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| WO-2015165340-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
| US-8288387-B2 | Napthalimide-benzimidazole hybrids as potential antitumor agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-10-16 | — | — | US | disclosed |
| US-20110166346-A1 | NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2011-07-07 | — | — | US | disclosed |
| US-20100292439-A1 | Use of Functionalized Onium Salts for Peptide Synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE` (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292439-A1 | Use of Functionalized Onium Salts for Peptide Synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE` (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292439-A1 | Use of Functionalized Onium Salts for Peptide Synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE` (FR) | 2010-11-18 | — | — | US | disclosed |
| WO-2009110000-A1 | NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOUR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008003836-A1 | USE OF FUNCTIONALIZED ONIUM SALTS FOR THE SYNTHESIS OF PEPTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-01-10 | — | — | WO | disclosed |
| US-7259174-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2007-08-21 | — | — | US | disclosed |
| US-20050267164-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES | 2005-12-01 | — | — | US | disclosed |
| EP-0533933-A1 | BISHETEROCYCLIC COMPOUND | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292439-A1 | Use of Functionalized Onium Salts for Peptide Synthesis | NPY1R, CNKSR1, NPBWR1 | ALDH1A1 4149/4885SMN1; SMN2 3248/4885MAPT 4038/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | ALDH1A1 1424/4885SMN1; SMN2 696/4885MAPT 3673/4885 |
| US-20050267164-A1 | Imidazolidinone compounds | MLX, EPX, ZYX | ALDH1A1 2388/4885SMN1; SMN2 223/4885MAPT 4299/4885 |
| US-20110166346-A1 | NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | NAP1L4, NAP1L1, CCNI | ALDH1A1 592/4885SMN1; SMN2 1870/4885MAPT 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.